Robert E. Bristow MD MBA

Obstetrics & Gynecology•Orange, CA

General Gynecology, Gynecologic Oncology

Professor and Chair Department of Obstetrics and Gynecology / University of California, Irvine

Join to View Full Profile

333 City Blvd WestSuite 1400Orange, CA 92868
Phone+1 714-456-8785

Education & Training

Johns Hopkins UniversityMBA, Business Administration, 2003 - 2008
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gynecologic Oncology, 1995 - 1998
Johns Hopkins UniversityResidency, Obstetrics and Gynecology, 1991 - 1995
Keck School of Medicine of the University of Southern CaliforniaClass of 1991

Certifications & Licensure

CA State Medical License 1995 - 2027
MD State Medical License 1998 - 2010
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2014
Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:San Diego Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Paclitaxel in Treating Patients With Ovarian Stromal Cancer Start of enrollment: 2000 Nov 20
Completed
Phase 2
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
ACTIVE_NOT_RECRUITING
PHASE3
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
Collecting Tumor Samples From Patients With Gynecological Tumors Start of enrollment: 1992 Jun 01
Completed
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 2014 Jul 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Surgical Management of Gynecologic Cancers.
Kiran H Clair, Juliet Wolford, Jason A Zell, Robert E Bristow
Hematology/oncology Clinics of North America. 2025-02-01
2 citations
Trends in endometrial cancer incidence in the United States by race/ethnicity and age of onset from 2000 to 2019.
Victoria E Rodriguez, Sora Park Tanjasiri, Annie Ro, Michael A Hoyt, Robert E Bristow
American Journal of Epidemiology. 2025-01-08
Trends in the incidence and mutational landscape of advanced uterine cancer.
Alex A Francoeur, Cheng-I Liao, Caitlin R Johnson, Chris Argueta, Chunqiao Tian
International Journal of Gynecological Cancer. 2025-01-01